Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 12, 2019Expects to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
-
Dec 9, 2019- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
-
Nov 21, 2019- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
-
Nov 6, 2019*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma